Recurrent genomic microdeletions have recently been identified in "common" sporadic epilepsies, those not obviously part of a genetic syndrome. 15q13.3, 15q11.2, and 16p13.3 microdeletions together underlie ∼3% of idiopathic generalized epilepsies (IGEs) ([@b13]; [@b7]; [@b23]). We identified 16p13.11 and other large microdeletions in ∼0.8% of patients with epilepsy ([@b12]). As more microdeletions are reported and technologies for the detection of these and other putatively causal variants become more accessible, interest in searching for such variants will increase.

A number of patients in our initial cohort had mesial temporal lobe epilepsy (MTLE) and had resective epilepsy surgery, and some were found to harbor particular microdeletions. The detection of a microdeletion might raise concern about its potential influence on outcome measures following epilepsy surgery, with regard to seizure control or other domains. The presence of a microdeletion could represent widespread brain involvement, similar to cognitive impairment or secondary generalized tonic--clonic seizures, both of which reduce chances of good outcome across various domains after epilepsy surgery ([@b21]; [@b29]). On the other hand, such microdeletions might not affect outcome, for example because of spatial variability in gene expression ([@b11]). We evaluated systematically the effect of large microdeletions on outcome after surgery in patients with MTLE.

Methods
=======

This work was approved by the relevant local research ethics committees. All patients provided written informed consent.

Microdeletions were identified as described previously ([@b12]). Only microdeletions \>1 Mb, or 16p13.11 microdeletions, were considered ([@b12]). We reevaluated clinical history and presurgical investigations \[magnetic resonance imaging (MRI) brain scan, video--electroencephalography (EEG) telemetry, neuropsychometry, neuropsychiatric assessment\]. Histopathology of the surgical specimen was reviewed. Postsurgical outcome was evaluated in terms of seizure control at 1 year and at last follow-up, using the International League Against Epilepsy (ILAE) outcome classification ([@b36]), antiepileptic drug changes, psychiatric outcome, neuropsychometry, and employment outcome.

Results
=======

Three thousand eight hundred twelve patients with epilepsy (\>90% with partial epilepsies) were genotyped and had a genome-wide screen to identify copy number variation. Ten patients with MTLE who had undergone therapeutic resection had large microdeletions. Follow-up duration after surgery ranged from 10--156 months. Three patients had 16p13.11 microdeletion and two had 15q11.2 microdeletion; the full range of microdeletions is listed in [Table 1](#tbl1){ref-type="table"}.

###### 

List of heterozygous 16p13.11 microdeletions or other microdeletions \>1 Mb in MTLE patients who had resective surgery

  Case ID   Cytoband         Breakpoints                 Size (Mb)   Gene list
  --------- ---------------- --------------------------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         16p13.11         chr16:15387380--16225138    0.8         *MPV17L*, *C16orf45*, *NDE1*, *MYH11*, *C16orf63*, *ABCC1*, *ABCC6*
  2         16p13.11         chr16:15387380--16225138    0.8         *MPV17L*, *C16orf45*, *NDE1*, *MYH11*, *C16orf63*, *ABCC1*, *ABCC6*
  3         7q31.32--31.33   chr7:123252578--126117199   2.9         *HYAL4*, *SPAM1*, *LOC136157*, *GPR37*, *POT1*, *GRM8*
  4         17p12            chr17:14040467--15411904    1.4         *COX10*, *CDRT15*, *HS3ST3B1*, *PMP22*, *TEKT3*, *CDRT4*, *FAM18B2*
  5         4q32.3           chr4:167446375--168643447   1.2         *SPOCK3*
  6         17q12            chr17:31922987--33333394    1.4         *ZNHIT3*, *MYO19*, *PIGW*, *GGNBP2*, *DHRS11*, *MRM1*, *LHX1*, *AATF*, *ACACA*, *C17orf78*, *TADA2L*, *DUSP14*, *AP1GBP1*, *DDX52*, *HNF1B*, *LOC284100*
  7         15q11.2          chr15:18285782--20868229    1.3         *OR4N4*, *NIPA2*, *NIPA1*, *TUBGCP5*, *CYFIP1*, *HERC2P2*, *A26B1 (POTEB)*, *OR4M2*, *AC131280.9*, *AC126603.9*, *AC116165.7*, *AC026495.13*, *AC025884.28*, *AC138701.3*, *AC127381.4*, *AC126335.16*, *AC091565.10*, *AC134980.3*, *AC138649.2*
  8         15q11.2          chr15:18822307--19852603    1.0         *AC025884.28*, *AC026495.13*, *OR4N4*, *OR4M2*, *AC131280.9*, *AC134980.3*, *AC126335.16*, *A26B1*
  9         4q35.2           chr4:189052964--190737252   1.97        *AC093909.2*, *AC020698.4*, *TRIML2*, *TRIML1*, *ZFP42*
  10        16p13.11         chr16:15387380--16198600    0.8         *MPV17L*, *C16orf45*, *NDE1*, *MYH11*, *C16orf63*, *ABCC1*, *ABCC6*

Demographic and clinical data are summarized in ([Table S1](#SD1){ref-type="supplementary-material"}), including details of the type of surgery and outcome of surgery across several domains, including seizure control. The histopathologic results from analysis of the surgical specimen are listed in [Table 2](#tbl2){ref-type="table"}.

###### 

Main findings of neuropathology analysis of temporal lobectomy specimen

  Case ID   Main pathologic findings in temporal neocortex                                 Main pathologic findings in hippocampus                                                                            Summary of main pathologic findings
  --------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------
  1         Small glioneuronal hamartoma in middle temporal gyrus white matter             Only CA1 available for analysis; neuronal loss not seen                                                            No hippocampal sclerosis but specimen incomplete. Hamartoma
  2         Focal neuronal loss and gliosis in superficial cortex in pole (TLS) ([@b32])   Neuronal loss and gliosis particularly in CA1 and CA4. Mild GCD                                                    Classical hippocampal sclerosis
  3         Cortex normal                                                                  Neuronal loss and gliosis particularly in CA1 and CA4. Moderate GCD                                                Classical hippocampal sclerosis
  4         Gliosis only. No dysplasia                                                     Incomplete representation of subfields. CA1 neuronal loss and gliosis. GCD                                         Classical hippocampal sclerosis
  5         Patchy cortical and white matter gliosis                                       Neuronal loss and gliosis particularly in CA1 and CA4. Moderate GCD                                                Classical hippocampal sclerosis
  6         Cortex normal                                                                  Neuronal loss in CA4 and CA1 and gliosis                                                                           Classical hippocampal Sclerosis
  7         Numerous corpora amylacea in white matter                                      Incomplete representation of subfields. CA1 and CA4 neuronal loss and gliosis. Mild GCD and some depletion of GC   Classical hippocampal sclerosis
  8         N/A[*a*](#tf2-1){ref-type="table-fn"}                                          Neuronal loss and gliosis particularly in CA1 and CA4                                                              Classical hippocampal sclerosis.
  9         N/A[*a*](#tf2-1){ref-type="table-fn"}                                          Moderate to marked astrogliosis                                                                                    Classical hippocampal sclerosis
  10        Patchy laminar reactive astrogliosis                                           Amygdala included, but hippocampal structures not present in specimen[*b*](#tf2-2){ref-type="table-fn"}            Nonspecific findings

These patients had selective amygdalohippocampectomy.

This patient had neocorticectomy and amygdalectomy.

GC(D), Granule cell (dispersion); N/A, not applicable; TLS, temporal lobe sclerosis ([@b32]).

Eight patients had histologically proven classical hippocampal sclerosis (HS) ([Table 2](#tbl2){ref-type="table"}). All were rendered seizure-free after surgery. All displayed clinical features "typical" of MTLE + HS ([@b35]) (Table S1). In all patients except one, antiepileptic drugs (AEDs) were reduced in number and/or daily dose during long-term follow-up. Two patients were off AEDs; they had remained seizure-free at last follow-up.

Another patient, with MRI-negative temporal lobe epilepsy, had a right neocorticectomy and amygdalectomy, with nonspecific findings at histopathology, and after 7 years of seizure freedom, began again to have infrequent partial seizures. One patient with a hamartoma had a right anterior temporal lobectomy, but was never rendered seizure-free. There were no unexpected findings in other domains during postsurgical follow-up.

Discussion
==========

In patients with drug-resistant MTLE + HS, surgery is more effective in stopping disabling seizures than medical treatment alone ([@b34]). Recent studies also suggest that such surgery can benefit longevity ([@b5]) and quality of life ([@b38]). Around one-third of patients who undergo surgery fail to become seizure-free, the causes for which are uncertain; the proportion not seizure-free increases at longer-term follow-up ([@b35]). Although several predictors of outcome are known or proposed at a group level, including presence of HS, absence of generalized tonic--clonic seizures, larger extent of mesiotemporal resection, and unilateral interictal epileptiform activity ([@b37]; [@b24]; [@b9]; [@b33]; [@b15]; [@b30]; [@b29]), there are no universally accepted outcome predictors for MTLE + HS at an individual level. Such predictors would assist in estimating risk/benefit ratio for each patient more accurately.

Genetic factors might be postulated to contribute to outcome, and indeed to causation of MTLE + HS. Familial MTLE exists ([@b1], [@b2]; [@b6]). Some argue that familial MTLE with HS/hippocampal atrophy is clinically indistinguishable from sporadic MTLE + HS ([@b19]; [@b10]). No genetic cause of familial MTLE is known. In addition, no genetic determinant for susceptibility to sporadic MTLE + HS, or for predicting outcome after epilepsy surgery, has been confirmed ([@b16]; [@b31]; [@b3], [@b4]; [@b18]).

Microdeletions are becoming recognized as an important potential genetic cause of, or predisposition to, a wide range of epilepsies. Although some microdeletions may be chance findings, large microdeletions are likely to be associated with disease ([@b25]), and we showed changes in gene expression with 16p13.11 microdeletions, and noted that many known epilepsy genes, for example, *KCNA1*, *GABRA1*, and *GABRG2*, can be involved in microdeletions ([@b12]). It is important to note that many of these microdeletions seem to act as risk factors rather than as the sole underlying cause, and that some microdeletions are found in people without epilepsy or a family history of epilepsy, although at much reduced frequency ([@b28]). Although more work is required to characterize microdeletions and their pathogenic mechanisms, significant microdeletions are likely to be found in many other patients, including those being considered for epilepsy surgery. Because these microdeletions might affect outcome after surgical treatment, it is important to systematically evaluate their influence.

The seizure-free rate in our patients with putatively pathogenic microdeletions seems as good as reported for cohorts in the literature ([@b22]; [@b29]; [@b8]). Although this observation must be tempered by the small size of our microdeletion cohort and requires further confirmation, we show that having a large microdeletion does not preclude seizure-free outcome after surgery for MTLE. Although our findings may relate to specific microdeletions, our seizure-free patients had seven different microdeletions, and had a good postsurgical outcome in other domains as well, not just seizure control (Table S1). The psychiatric outcome varied, with presurgical psychiatric comorbidity common in the cases with postsurgical psychiatric issues, as reported previously in the literature ([@b17]).

There are other examples in the literature of epilepsies with a genetic basis and a good outcome after resective surgery for drug-resistant seizures. In families with *SCN1B*-positive genetic epilepsy with febrile seizures plus (GEFS+), an excellent outcome has been reported after anterior temporal lobectomy for affected individuals with drug-resistant MTLE + HS ([@b26]). A small series of patients with tuberous sclerosis complex, with confirmed mutations in the *TSC1* (n = 2) and *TSC2* (n = 2) genes, had discrete epileptogenic brain lesions that were resected, and were seizure-free on AEDs at last follow-up after surgery ([@b14]). Postsurgical seizure outcome in patients with familial MTLE with HS/hippocampal atrophy, for which no known genetic cause is actually yet known, does not differ from that in sporadic MTLE with HS/hippocampal atrophy ([@b20]).

Our findings suggest that large microdeletions do not necessarily preclude a good prognosis following epilepsy surgery, if surgery is a reasonable option based on concordance of other data during presurgical evaluation. Further studies will be important to firmly establish the mechanisms of MTLE associated with large microdeletions. As more putatively causal genetic variants of all classes are uncovered, it will also become important to address their impact on clinical management.
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**Table S1.** Clinical data, including preoperative investigations, type of surgery, and post-surgical outcome.
